annual EBITDA:
-$131.18M-$36.81M(-39.01%)Summary
- As of today (July 3, 2025), KALV annual EBITDA is -$131.18 million, with the most recent change of -$36.81 million (-39.01%) on April 30, 2024.
- During the last 3 years, KALV annual EBITDA has fallen by -$73.79 million (-128.59%).
- KALV annual EBITDA is now -7357.48% below its all-time high of -$1.76 million, reached on December 31, 2012.
Performance
KALV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$41.19M+$4.39M(+9.64%)Summary
- As of today (July 3, 2025), KALV quarterly EBITDA is -$41.19 million, with the most recent change of +$4.39 million (+9.64%) on January 31, 2025.
- Over the past year, KALV quarterly EBITDA has dropped by -$12.37 million (-42.92%).
- KALV quarterly EBITDA is now -3503.76% below its all-time high of -$1.14 million, reached on December 31, 2013.
Performance
KALV quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$180.54M-$12.37M(-7.36%)Summary
- As of today (July 3, 2025), KALV TTM EBITDA is -$180.54 million, with the most recent change of -$12.37 million (-7.36%) on January 31, 2025.
- Over the past year, KALV TTM EBITDA has dropped by -$77.52 million (-75.24%).
- KALV TTM EBITDA is now -15695.71% below its all-time high of -$1.14 million, reached on December 31, 2013.
Performance
KALV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
KALV EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -39.0% | -42.9% | -75.2% |
| 3 y3 years | -128.6% | -55.2% | -106.8% |
| 5 y5 years | -345.5% | -227.2% | -351.1% |
KALV EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -62.5% | at low | -262.9% | +17.3% | -123.6% | at low |
| 5 y | 5-year | -227.8% | at low | -366.6% | +17.3% | -351.1% | at low |
| alltime | all time | -7357.5% | at low | -3503.8% | +17.3% | <-9999.0% | at low |
KALV EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2025 | - | -$41.19M(-9.6%) | -$180.54M(+7.4%) |
| Oct 2024 | - | -$45.58M(+3.6%) | -$168.18M(+10.5%) |
| Jul 2024 | - | -$43.99M(-11.6%) | -$152.14M(+11.0%) |
| Apr 2024 | -$131.18M(+39.0%) | -$49.78M(+72.7%) | -$137.05M(+33.0%) |
| Jan 2024 | - | -$28.82M(-2.5%) | -$103.03M(+2.1%) |
| Oct 2023 | - | -$29.55M(+2.2%) | -$100.95M(+4.0%) |
| Jul 2023 | - | -$28.90M(+83.4%) | -$97.11M(+2.9%) |
| Apr 2023 | -$94.37M(+16.9%) | -$15.76M(-41.1%) | -$94.37M(+4.9%) |
| Jan 2023 | - | -$26.75M(+4.0%) | -$89.97M(+0.2%) |
| Oct 2022 | - | -$25.71M(-1.7%) | -$89.75M(+2.6%) |
| Jul 2022 | - | -$26.16M(+130.4%) | -$87.52M(+8.4%) |
| Apr 2022 | - | -$11.35M(-57.2%) | -$80.75M(-7.5%) |
| Apr 2022 | -$80.75M(+40.7%) | - | - |
| Jan 2022 | - | -$26.53M(+13.0%) | -$87.30M(+19.1%) |
| Oct 2021 | - | -$23.48M(+21.1%) | -$73.28M(+17.3%) |
| Jul 2021 | - | -$19.38M(+8.3%) | -$62.45M(+8.8%) |
| Apr 2021 | -$57.39M(+43.4%) | -$17.90M(+43.0%) | -$57.39M(+18.8%) |
| Jan 2021 | - | -$12.52M(-1.0%) | -$48.31M(-0.1%) |
| Oct 2020 | - | -$12.65M(-11.6%) | -$48.38M(+7.8%) |
| Jul 2020 | - | -$14.31M(+62.2%) | -$44.89M(+12.2%) |
| Apr 2020 | -$40.02M(+35.9%) | -$8.83M(-29.9%) | -$40.02M(-5.5%) |
| Jan 2020 | - | -$12.59M(+37.4%) | -$42.33M(+16.6%) |
| Oct 2019 | - | -$9.16M(-3.0%) | -$36.30M(+13.7%) |
| Jul 2019 | - | -$9.44M(-15.2%) | -$31.93M(+8.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Apr 2019 | -$29.44M(+58.9%) | -$11.14M(+69.9%) | -$29.44M(+38.7%) |
| Jan 2019 | - | -$6.56M(+36.9%) | -$21.22M(+11.9%) |
| Oct 2018 | - | -$4.79M(-31.2%) | -$18.96M(-5.5%) |
| Jul 2018 | - | -$6.96M(+138.5%) | -$20.06M(+8.3%) |
| Apr 2018 | -$18.52M(-16.9%) | -$2.92M(-32.1%) | -$18.52M(-10.4%) |
| Jan 2018 | - | -$4.30M(-27.1%) | -$20.68M(-15.6%) |
| Oct 2017 | - | -$5.89M(+8.7%) | -$24.50M(+16.7%) |
| Jul 2017 | - | -$5.42M(+6.8%) | -$21.00M(-6.8%) |
| Apr 2017 | -$22.30M(+47.2%) | -$5.08M(-37.5%) | -$22.52M(-5.9%) |
| Jan 2017 | - | -$8.12M(+240.3%) | -$23.93M(+12.1%) |
| Sep 2016 | - | -$2.38M(-65.7%) | -$21.35M(-10.4%) |
| Jun 2016 | - | -$6.94M(+7.1%) | -$23.83M(-7.3%) |
| Apr 2016 | -$15.15M(-35.6%) | - | - |
| Mar 2016 | - | -$6.49M(+17.1%) | -$25.69M(+9.2%) |
| Dec 2015 | -$23.52M(+192.2%) | -$5.54M(+13.8%) | -$23.52M(+6.3%) |
| Sep 2015 | - | -$4.86M(-44.8%) | -$22.12M(+5.9%) |
| Jun 2015 | - | -$8.81M(+104.1%) | -$20.88M(+42.9%) |
| Apr 2015 | -$8.05M(-34.1%) | - | - |
| Mar 2015 | - | -$4.32M(+4.4%) | -$14.62M(+19.6%) |
| Dec 2014 | -$12.22M(+133.0%) | -$4.13M(+14.2%) | -$12.22M(+32.4%) |
| Sep 2014 | - | -$3.62M(+42.4%) | -$9.23M(+64.5%) |
| Jun 2014 | - | -$2.54M(+32.1%) | -$5.61M(+82.9%) |
| Mar 2014 | - | -$1.93M(+68.4%) | -$3.07M(+168.4%) |
| Dec 2013 | -$5.25M(+198.2%) | -$1.14M | -$1.14M |
| Dec 2012 | -$1.76M | - | - |
FAQ
- What is KalVista Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals annual EBITDA year-on-year change?
- What is KalVista Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals quarterly EBITDA year-on-year change?
- What is KalVista Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals TTM EBITDA year-on-year change?
What is KalVista Pharmaceuticals annual EBITDA?
The current annual EBITDA of KALV is -$131.18M
What is the all time high annual EBITDA for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high annual EBITDA is -$1.76M
What is KalVista Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, KALV annual EBITDA has changed by -$36.81M (-39.01%)
What is KalVista Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of KALV is -$41.19M
What is the all time high quarterly EBITDA for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high quarterly EBITDA is -$1.14M
What is KalVista Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, KALV quarterly EBITDA has changed by -$12.37M (-42.92%)
What is KalVista Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of KALV is -$180.54M
What is the all time high TTM EBITDA for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high TTM EBITDA is -$1.14M
What is KalVista Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, KALV TTM EBITDA has changed by -$77.52M (-75.24%)